Mutation frequency and copy number alterations determine prognosis and metastatic tropism in 60,000 clinical cancer samples

Nicola Calonaci,Eriseld Krasniqi,Stefano Scalera,Giorgia Gandolfi,Salvatore Milite,Biagio Ricciuti,Marcello Maugeri-Saccà,Giulio Caravagna

DOI: https://doi.org/10.1101/2024.05.13.24307238

2024-05-13

Abstract:The intricate interplay between somatic mutations and copy number alterations critically influences tumour evolution and patient prognosis. Traditional genomic studies often overlook this interplay by analysing these two biomarker types in isolation. Leveraging an innovative computational model capable of detecting allele-specific copy number alterations from clinical targeted panels without matched normal, we conducted a comprehensive analysis of over 500,000 mutations across 60,000 clinical samples spanning 39 cancer types. Our findings uncovered 11 genes and 6 hotspots exhibiting recurrent tumour-specific patterns of co-existing mutations and copy-number alterations across 17 tumours. By stratifying more than 24,000 patients based on these composite genotypes across multiple oncogenes and tumour suppressor genes, we identified 66 groups with distinct prognostic significance, 25% more than using a standard mutation-centric stratification. Notably, 7 groups displayed a heightened propensity for metastasis, while 16 were associated with site-specific patterns of metastatic dissemination. This augmented insight into genomic drivers enhances our understanding of cancer progression and metastasis, holding the potential to significantly foster biomarker discovery.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore how the complex interactions between somatic mutations and copy number alterations (CNAs) affect tumor evolution, patient prognosis, and metastatic propensity. Traditional genomics studies usually analyze these two types of biomarkers separately, while this paper can detect allele - specific copy number alterations from clinical targeted panels without matched normal samples by using an innovative computational model. The research team conducted a comprehensive analysis of more than 500,000 mutations in over 60,000 clinical samples, covering 39 cancer types.

### Main research contents:
1. **Innovative computational model**: Developed an open - source tool named INCOMMON, which can infer allele - specific copy numbers and mutation multiplicities from clinical targeted sequencing data.
2. **Large - scale data analysis**: Used INCOMMON to analyze more than 500,000 mutations in over 60,000 clinical samples, revealing the patterns of co - existing mutations and copy number alterations in 11 genes and 6 hotspots in 17 tumors.
3. **Patient stratification**: Based on these compound genotypes, more than 24,000 patients were divided into 66 groups with different prognostic implications, which is 25% more than the traditional mutation - centered stratification method.
4. **Metastatic propensity**: Identified 7 groups with a higher metastatic propensity and 16 groups related to specific - site metastasis patterns.

### Research significance:
- **Enhanced understanding**: By comprehensively analyzing mutations and copy number alterations, the understanding of cancer progression and metastasis mechanisms has been enhanced.
- **Biomarker discovery**: Provides a new perspective, which is helpful for discovering new biomarkers, thereby improving cancer diagnosis and treatment strategies.
- **Clinical application**: Promotes the transformation of clinical sequencing towards a more integrated and comprehensive method, which is of great significance for biomarker discovery and target identification.

### Specific findings:
- **Genes and hotspots**: Identified 11 cancer - related genes and 6 hotspots, where mutations and copy number alterations occur frequently in multiple tumors.
- **Patient prognosis**: By combining the information of mutations and copy number alterations, patients were divided into 66 groups with different prognostic implications, with a 24.5% improvement in resolution compared to traditional methods.
- **Metastatic propensity**: Identified 7 groups with a higher metastatic propensity, such as LOH of CDH1, amplification of E542K and E545K in PIK3CA in breast cancer, E746_A750del in EGFR in lung adenocarcinoma, and amplification of PIK3CA in endometrial cancer.
- **Metastasis pattern**: Explained 16 groups related to specific - site metastasis patterns, such as LOH of PTPRD spreading from primary melanoma to the brain, G12V and G12D in KRAS spreading to the lymphatic system without amplification and to the liver with amplification in pancreatic cancer.

Through these findings, this study provides new insights into key issues in cancer biology, such as survival patterns and metastatic spread, and lays the foundation for future biomarker discovery and target identification.